Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01015963

NCT01015963
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You must have already been registered in a previous study called CALGB 9871
  • There must be stored biological samples from you held at the CALGB Pathology Coordinating Office that are sufficient in quantity and quality for the study's purposes

Who may not be able to join:

  • No specific exclusion criteria were listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Alliance for Clinical Trials in Oncology
Registry
clinicaltrials_gov
Start date
1 October 2008
Est. completion
1 January 2013

Primary endpoints

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure; Incidence of SLC01B3 polymorphism (rs11045585)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov